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Adiponectin, the most abundant secreted adipokine, has received great attention from the scientific
community since its discovery [1]. The huge number of studies is justified by the insulin-sensitizing
role and the beneficial effects of adiponectin in diabetic conditions [2,3]. Over the years, a large body
of evidence has supported a pleiotropic role of the hormone in different tissues in which it influences
varied physiological aspects both in healthy and in diseased conditions.
This Special Issue, entitled “Mechanisms of Adiponectin Action”, shows the pleiotropic role of
adiponectin by presenting three research articles and seven reviews focused on recent findings about
adiponectin in different target tissues. The Special Issue contains two reviews about adiponectin in
skeletal muscle, a classical adiponectin target tissue, in which the hormone affects both metabolic [4]
and regenerative properties [5]. Krause et al. report a close relationship between physical exercise and
expression and circulating levels of adiponectin in both healthy and diseased population. Indeed, a
higher adiponectin level is associated with greater physical activity, while some conditions, such as
inactive obese, pre-diabetic, and diabetic patients, are characterized by decreased adiponectin levels.
The restoration of proper adiponectin levels can be achieved with physical exercise, and this leads to
increased insulin sensitivity [6]. Gamberi et al. discusses the current knowledge about adiponectin in
myopathies (both non-inherited/acquired and inherited myopathies). The paper reports that some
myopathies (as Duchenne muscular dystrophy and collagen VI-related myopathies) are characterized
by a decreased circulating adiponectin level and that hormone replenishment induces beneficial effects
in the diseased muscles [7]. Studies about the involvement of adiponectin in cancer have been growing
in the last years. Parida et al. report how obesity and adiposity are closely related to cancer progression
in several types of tumors (such as liver, pancreatic, prostate, and colorectal cancers). Obesity acts
by dysregulating adipokine production, leading to the upregulation of oncogenic adipokines, such
as leptin, and the downregulation of adiponectin, which plays a protective role in obesity-associated
cancers [8]. About the relationship between obesity and cancer, Gelsomino et al. describe the role of
adiponectin in the onset of obesity-associated female cancers (such as cervical, ovarian, endometrial, and
breast cancers), reporting that adiponectin exerts anti-proliferative actions in some female cancers [9].
Barbe et al. report an overview of the expression levels and signaling pathways of adiponectin in
male and female reproductive tract, from gametogenesis to embryo implantation and embryonal
development. In addition, the authors describe some diseases associated with infertility, characterized
by altered adiponectin levels (such as polycystic ovary syndrome, ovarian and endometrial cancers,
endometriosis, gestational diseases, preeclampsia, and foetal growth restriction) [10]. Smolinska
et al. report a research article describing a comparative transcriptomic study performed in control
and adiponectin-treated endometrial tissues isolated from 15- to 16-day-pregnant pigs. The findings
evidence that adiponectin affects processes important for reproductive success, such as cell proliferation,
cell adhesion, and synthesis of steroids, prostaglandins, and cytokines [11]. The anti-atherogenic role
of adiponectin has been widely recognized. Yanai et al. illustrate the mechanisms underlying the
anti-atherogenic role of the hormone, describing methods (such as weight loss, exercise, administration
of nutritional factors and anti-diabetic drugs) leading to the rise of circulating adiponectin, which have
been proven to have protective effects against atherosclerotic progression [12]. A role of adiponectin
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in the mitigation of renal injury due to diabetes has been proposed. Kim et al. highlight recent
advances about adiponectin and kidney diseases, describing adiponectin signaling pathways in healthy
and disease conditions. In particular, the review discusses the possible strategies for upregulating
adiponectin and adiponectin receptors and the possible use of the receptor agonist AdipoRon in
the amelioration of overt diabetic kidney disease [13]. Furthermore, this Special Issue contains two
research articles regarding adiponectin involvement in human follicular dermal papilla cells and
the interaction of adiponectin with nerve growth factor β (NGFβ) and secreted protein acidic and
rich in cysteine (SPARC). Park et al. report that kojyl cinnamate ester derivatives and Seletinoid G
promote adiponectin secretion by human follicular dermal papilla cells. In addition, cell medium
containing secreted adiponectin induces the expression of hair growth-related factors, thus suggesting
an involvement of the hormone in the promotion of hair growth in humans [14]. Finally, Okura et al.
investigate the interaction between adiponectin and NGFβ and SPARC. Surface plasmon resonance
analysis demonstrated a physical interaction between adiponectin and NGFβ, and this interaction was
confirmed in neuronal cultured PC12 cells [15].
Collectively, the papers reported in this Special Issue reinforce the idea that adiponectin plays an
important role at the systemic level and that hypoadiponectinemia is associated with many diseases.
The exogenous administration of adiponectin has often beneficial effects in diseased tissues, suggesting
that the planning of new drugs able to activate adiponectin signaling could be a new tool for the
amelioration of several pathologies.
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